Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04225312 (ClinicalTrials.gov)	February 3, 2020	3/1/2020	Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis	Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis	Relapsing Remitting Multiple Sclerosis	Drug: Personalized extended interval dosing of natalizumab;Drug: Standard interval dosing	VU University Medical Center	Stichting MS Research;Innovatiefonds Zorgverzekeraard	Recruiting	18 Years	N/A	All	300	Phase 4	Netherlands
2	EUCTR2019-002566-13-NL (EUCTR)	19/12/2019	29/10/2019	Personalizing the treatment with natalizumab in patients with multiple sclerosis	Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis - NEXT-MS	Relapsing remitting multiple sclerosis MedDRA version: 20.1;Level: LLT;Classification code 10070425;Term: Multiple sclerosis exacerbation;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Tysabri Product Name: natalizumab	Amsterdam University Medical Center	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	300	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	Netherlands